{"product_id":"servier-five-forces-analysis","title":"Servier Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eServier faces moderate supplier power and regulatory pressure, while patent cliffs and biosimilar competition heighten threat of substitutes and new entrants in select markets; buyer power varies by product mix and reimbursement dynamics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized API Manufacturing Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eServier depends on highly specialized active pharmaceutical ingredients (APIs) for its oncology and cardiovascular drugs, with fewer than 10 certified global suppliers able to meet EMA\/FDA purity and regulatory specs as of 2025; that concentration raises supplier leverage. \u003c\/p\u003e\n\u003cp\u003eSupply disruptions—recall: a 2023 API plant outage caused ~15–25% short-term production cuts industry-wide—would likely delay Servier timelines and raise COGS by an estimated 5–12% per affected product. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Switching Costs for Validated Sources\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRegulatory bodies like EMA and FDA demand supplier validation, so Servier faces steep re‑certification costs—industry estimates peg single-site revalidation at €2–5m and 9–18 months, creating supplier lock‑in; suppliers can thus extract better terms during renegotiations. In 2024 pharma surveys showed 62% of mid‑sized firms avoided supplier swaps due to validation time, so Servier often finds transition capital and time outweigh savings from cheaper vendors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Global CDMOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConsolidation among global CDMOs cut independent suppliers by ~30% since 2018, leaving the top 10 firms holding ~60% of capacity by 2024, boosting their pricing power and bargaining leverage over mid-sized pharmas like Servier.\u003c\/p\u003e\n\u003cp\u003eLarger CDMOs can prioritize high-volume clients, raising spot rates—average biologics fill\/finish contract prices rose ~18% in 2023—so Servier needs multi-year supply agreements and capacity reservations to secure priority access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property on Upstream Technologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers of proprietary gene-editing platforms and single-cell analysis systems exert strong bargaining power for Servier, since few direct substitutes exist and patents concentrate supply; top vendors like Illumina and 10x Genomics controlled \u0026gt;40% of their niches in 2024.\u003c\/p\u003e\n\u003cp\u003eAs Servier expands in immuno-inflammation and targeted therapies, its dependence on these niche providers rises, raising R\u0026amp;D input costs; segment-specific licensing and consumables margins often exceed 30%.\u003c\/p\u003e\n\u003cp\u003eThat IP barrier lets suppliers keep premium pricing for essential reagents, instruments, and software, pressuring Servier’s gross margins on early-stage programs and increasing capex and OPEX predictability risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh supplier concentration: \u0026gt;40% market share by leading platform vendors (2024)\u003c\/li\u003e\n\u003cli\u003ePremium pricing: consumables\/instrument margins often \u0026gt;30%\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D exposure: deeper immuno-targeting increases reliance on niche IP\u003c\/li\u003e\n\u003cli\u003eFinancial risk: higher capex\/OPEX and margin pressure on early programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStringent Regulatory Compliance and ESG Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers must meet evolving global ESG rules to remain Servier partners, raising their compliance costs which are often passed to Servier as higher procurement prices; a 2024 EY survey found 62% of pharma suppliers expect procurement cost increases of 5–12% to meet sustainability mandates.\u003c\/p\u003e\n\u003cp\u003eSuppliers already compliant with 2025-era sustainability mandates gain pricing power and lower switching costs, strengthening their bargaining position; MSCI data shows compliant suppliers saw a 7% revenue premium in 2024.\u003c\/p\u003e\n\u003cp\u003eServier faces concentrated supplier leverage where certified green raw-material suppliers supply ~35% of key inputs, increasing supplier influence on margins and timelines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e62% suppliers expect 5–12% cost rise (EY, 2024)\u003c\/li\u003e\n\u003cli\u003eCompliant suppliers earned ~7% revenue premium (MSCI, 2024)\u003c\/li\u003e\n\u003cli\u003e~35% of key inputs from certified green suppliers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier concentration, scarce APIs and ESG squeeze margins—5–12% cost shocks, €2–5m revalidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh supplier concentration (top CDMOs ~60% capacity, 2024) and scarce certified API\/vendors (fewer than 10 for key oncology\/CV APIs, 2025) give suppliers strong leverage, raising COGS 5–12% on disruptions and forcing costly revalidation (€2–5m, 9–18 months). ESG compliance adds 5–12% procurement cost pressure (EY 2024); niche platform vendors hold \u0026gt;40% share, driving \u0026gt;30% margins on consumables.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop CDMO capacity\u003c\/td\u003e\n\u003ctd\u003e~60% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCertified API suppliers\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisruption COGS impact\u003c\/td\u003e\n\u003ctd\u003e5–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevalidation cost\/time\u003c\/td\u003e\n\u003ctd\u003e€2–5m; 9–18m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eESG cost rise\u003c\/td\u003e\n\u003ctd\u003e5–12% (EY 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Servier, this Porter's Five Forces analysis uncovers key drivers of competition, supplier and buyer influence, entry barriers, substitute threats, and emerging disruptors that shape pricing power and long-term profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eClear, one-sheet Porter’s Five Forces for Servier—quickly pinpoint competitive pressures and strategic levers to relieve decision-making stress.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated Power of National Health Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn France and across Europe, single-payer national health systems are dominant buyers, giving governments concentrated bargaining power over Servier; in 2024 France’s Assurance Maladie covered ~75% of healthcare spending, pushing hard on prices.\u003c\/p\u003e\n\u003cp\u003eTheir scale forces steep discounts and rebates—public payers commonly secure 20–40% off list prices—and can delist drugs from reimbursement, directly cutting Servier’s market access and revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth of Group Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn the US and other private-heavy markets, Group Purchasing Organizations (GPOs) and Pharmacy Benefit Managers (PBMs) concentrate buying power—PBMs covered 92% of commercially insured lives in the US by 2024—so they negotiate steep rebates and formulary placements for Servier’s drugs. Missing preferred tiers can cut volumes sharply; a tier downgrade typically reduces prescriptions 20–60%, risking rapid market share loss to similar therapies. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncreasing Price Sensitivity of Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs out-of-pocket costs for specialty drugs rose—US median deductible up 45% from 2016–2024 to about $1,700—patients actively choose treatments; 39% reported switching to lower-cost options in 2023. High co-pays push uptake of generics and biosimilars (global biosimilar market hit $17.8B in 2024). Servier must prove superior clinical value and real-world outcomes to justify premium pricing to patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Value-Based Pricing Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy end-2025, roughly 30–40% of US and EU payer contracts tie payment to outcomes, shifting bargaining power to customers who pay for demonstrated efficacy not just drugs.\u003c\/p\u003e\n\u003cp\u003eServier must boost RWE investment—estimated €50–100M annually for late-stage portfolios—to meet outcome data demands and secure formulary placement.\u003c\/p\u003e\n\u003cp\u003eFailure to supply robust RWE raises price pressure and volume risk, compressing margins by an estimated 5–12% on key products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e30–40% outcome-based contracts by 2025\u003c\/li\u003e\n\u003cli\u003e€50–100M annual RWE spend needed\u003c\/li\u003e\n\u003cli\u003e5–12% margin compression risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Generic and Biosimilar Alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe availability of bioequivalent generics for older Servier cardiovascular and diabetes drugs gives buyers low-cost alternatives; global generic market share for small-molecule cardiometabolic drugs reached about 78% by volume in 2024, increasing buyer leverage.\u003c\/p\u003e\n\u003cp\u003eWhen patents expire, bargaining power shifts to buyers who often pick among multiple generics priced 60–90% below originators, pressuring Servier’s margins and market share.\u003c\/p\u003e\n\u003cp\u003eServier must keep launching protected biologics or novel formulations; R\u0026amp;D spend rose to €620m in 2024 so the firm can migrate customers to newer, patent-protected options.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGenerics share ~78% volume (2024)\u003c\/li\u003e\n\u003cli\u003ePrice cuts 60–90% vs originator\u003c\/li\u003e\n\u003cli\u003eServier R\u0026amp;D €620m (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers’ leverage squeezes margins: payers, PBMs, generics \u0026amp; RWE costs drive 5–12% risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers (national payers, PBMs, GPOs, patients) hold strong leverage: public payers drive 20–40% discounts and Assurance Maladie covered ~75% of French healthcare spend (2024); PBMs covered 92% of US commercial lives (2024); generics = ~78% volume (2024) with 60–90% price cuts; 30–40% outcome-based contracts by 2025; Servier needs €50–100M RWE\/year; margin risk 5–12%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic payer share France\u003c\/td\u003e\n\u003ctd\u003e~75% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM coverage US\u003c\/td\u003e\n\u003ctd\u003e92% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics volume\u003c\/td\u003e\n\u003ctd\u003e~78% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutcome contracts\u003c\/td\u003e\n\u003ctd\u003e30–40% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRWE spend need\u003c\/td\u003e\n\u003ctd\u003e€50–100M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMargin compression risk\u003c\/td\u003e\n\u003ctd\u003e5–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eServier Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Servier Porter’s Five Forces analysis you’ll receive immediately after purchase—no placeholders, no mockups, fully formatted and ready to download for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747285578105,"sku":"servier-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/servier-five-forces-analysis.png?v=1772197115","url":"https:\/\/matrixbcg.com\/products\/servier-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}